Serotonin 2C receptor antagonists induce fast-onset antidepressant effects

Molecular Psychiatry

Volumn 19, Issue 10, 2014, Pages 1106-1114

  Opal, M D ^a   Klenotich, S C ^a   Morais, M ^b,c   Bessa, J ^b,c   Winkle, J ^a   Doukas, D ^a   Kay, L J ^a   Sousa, N ^b,c   Dulawa, S M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

Author keywords

Antidepressant; BDNF; eEF; mTOR; Neuronal remodeling

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 [5 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL] 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ECOPIPAM; ELONGATION FACTOR 2; FLUOXETINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; S6 KINASE; CREB1 PROTEIN, MOUSE; DOPAMINE 1 RECEPTOR; EEF2K PROTEIN, MOUSE; ELONGATION FACTOR 2 KINASE; MTOR PROTEIN, MOUSE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN ATROPHY; CLIMBING; CONTINUOUS INFUSION; CONTROLLED STUDY; DENDRITIC SPINE; ENZYME ACTIVATION; FEMALE; FORCED SWIM TEST; INTRACELLULAR SIGNALING; LOCOMOTION; LONG TERM CARE; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; VENTRAL TEGMENTUM; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; MENTAL STRESS; METABOLISM; OLFACTORY BULB; PATHOLOGY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; TIME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; CITALOPRAM; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; ELONGATION FACTOR 2 KINASE; FEMALE; MICE, INBRED BALB C; OLFACTORY BULB; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D1; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84922771522     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.144     Document Type: Article

References (53)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-3105.
2. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13: 57-66.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
5. Zarate Jr. CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of general psychiatry 2006; 63: 856-864.
6. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006; 63: 1121-1129.
7. Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology 2010; 35: 2479-2488.
8. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-964.
9. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95.
10. Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F et al. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology 2008; 199: 549-568.
11. de Boer TH, Nefkens F, van Helvoirt A, van Delft AM. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Therap 1996; 277: 852-860.
12. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology 1996; 126: 234-240.
13. Jenck F, Moreau JL, Mutel V, Martin JR. Brain 5-HT1C receptors and antidepressants. Progr Neuro-Psychopharmacol Biol Psychiatry 1994; 18: 563-574.
14. Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993; 231: 223-229.
15. Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009; 23(Suppl 2): 27-34.
16. Sansone RA, Sansone LA. Agomelatine: a novel antidepressant. Innov Clin Neurosci 2011; 8: 10-14.
17. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009; 10: 117-126.
18. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004; 29: 1321-1330.
19. Holick KA, Lee DC, Hen R, Dulawa SC. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 2008; 33: 406-417.
20. Jiao J, Nitzke AM, Doukas DG, Seiglie MP, Dulawa SC. Antidepressant response to chronic citalopram treatment in eight inbred mouse strains. Psychopharmacology 2011; 213: 509-520.
21. Shanahan NA, Velez LP, Masten VL, Dulawa SC. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry 2011; 70: 1039-1048.
22. van der Stelt HM, Breuer ME, Olivier B, Westenberg HG. Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Bioll Psychiatry 2005; 57: 1061-1067.
23. Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry 2009; 14: 764-773.
24. Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S et al. A molecular signature of depression in the amygdala. Am J Psychiatry 2009; 166: 1011-1024.
25. Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 2013; 493: 532-536.
26. Breuer ME, Groenink L, Oosting RS, Westenberg HG, Olivier B. Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats. Biol Psychiatry 2007; 61: 990-995.
27. Mar A, Spreekmeester E, Rochford J. Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety. Pharmacol Biochem Behav 2002; 73: 703-712.
28. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005; 52: 90-110.
29. Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000; 20: 4030-4036.
30. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35-41.
31. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
32. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011; 69: 754-761.
33. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007; 55: 712-725.
34. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci 2010; 13: 1161-1169.
35. Dulawa SC, Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 2005; 29: 771-783.
36. Honig G, Jongsma ME, van der Hart MC, Tecott LH. Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain. PLoS One 2009; 4: e6797.
37. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005; 29: 627-647.
38. Ibarguen-Vargas Y, Surget A, Vourc'h P, Leman S, Andres CR, Gardier AM et al. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 2009; 202: 245-251.
39. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
40. Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005; 26: 631-638.
41. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I et al. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008; 1211: 37-43.
42. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012; 35: 47-56.
43. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-3268.
44. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med 2004; 5: 11-25.
45. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 2004; 101: 10827-10832.
46. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008; 63: 642-649.
47. Di Matteo V, Cacchio M, Di Giulio C, Esposito E. Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 2002; 71: 727-734.
48. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP et al. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 2000; 36: 205-221.
49. Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 2013; doi:10.1016/j.biopsych.2013.04.025.
50. Mnie-Filali O, Faure C, Lambás-Señas L, El Mansari M, Belblidia H, Gondard E et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011; 36: 1275-1288.
51. Lucas G, Debonnel G. 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur J Neurosci 2002; 16: 817-822.
52. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999; 38: 1195-1205.
53. Sotty F, Folgering JH, Brennum LT, Hogg S, Mørk A, Hertel P et al. Relevance of dorsal raphe nucleus firing in serotonin 5-HT(2C) receptor blockade-induced augmentation of SSRIs effects. Neuropharmacology 2009; 57: 18-24.